These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37905858)

  • 21. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia.
    Mesulam MM; Weintraub S; Rogalski EJ; Wieneke C; Geula C; Bigio EH
    Brain; 2014 Apr; 137(Pt 4):1176-92. PubMed ID: 24574501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets.
    Hamzé R; Delangre E; Tolu S; Moreau M; Janel N; Bailbé D; Movassat J
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute neuropathological consequences of short-term mechanical ventilation in wild-type and Alzheimer's disease mice.
    Lahiri S; Regis GC; Koronyo Y; Fuchs DT; Sheyn J; Kim EH; Mastali M; Van Eyk JE; Rajput PS; Lyden PD; Black KL; Ely EW; D Jones H; Koronyo-Hamaoui M
    Crit Care; 2019 Feb; 23(1):63. PubMed ID: 30795776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes.
    Madonna R; Doria V; Minnucci I; Pucci A; Pierdomenico DS; De Caterina R
    J Cell Mol Med; 2020 Nov; 24(21):12331-12340. PubMed ID: 32940423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
    Grothe MJ; Sepulcre J; Gonzalez-Escamilla G; Jelistratova I; Schöll M; Hansson O; Teipel SJ;
    Brain; 2018 Sep; 141(9):2755-2771. PubMed ID: 30016411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients.
    Cehic MG; Muir CA; Greenfield JR; Hayward C; Jabbour A; Keogh A; Kotlyar E; Muthiah K; Macdonald PS
    Transplant Direct; 2019 May; 5(5):e450. PubMed ID: 31165085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
    Tikkanen I; Narko K; Zeller C; Green A; Salsali A; Broedl UC; Woerle HJ;
    Diabetes Care; 2015 Mar; 38(3):420-8. PubMed ID: 25271206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer's Disease and Type 2 Diabetes.
    Carranza-Naval MJ; Del Marco A; Hierro-Bujalance C; Alves-Martinez P; Infante-Garcia C; Vargas-Soria M; Herrera M; Barba-Cordoba B; Atienza-Navarro I; Lubian-Lopez S; Garcia-Alloza M
    Front Aging Neurosci; 2021; 13():741923. PubMed ID: 34975451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease.
    Nicolls MR
    Curr Alzheimer Res; 2004 Feb; 1(1):47-54. PubMed ID: 15975085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telomere shortening reduces Alzheimer's disease amyloid pathology in mice.
    Rolyan H; Scheffold A; Heinrich A; Begus-Nahrmann Y; Langkopf BH; Hölter SM; Vogt-Weisenhorn DM; Liss B; Wurst W; Lie DC; Thal DR; Biber K; Rudolph KL
    Brain; 2011 Jul; 134(Pt 7):2044-56. PubMed ID: 21672962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease.
    Du F; Yu Q; Yan S; Hu G; Lue LF; Walker DG; Wu L; Yan SF; Tieu K; Yan SS
    Brain; 2017 Dec; 140(12):3233-3251. PubMed ID: 29077793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Somatic pathology in elderly and senile persons suffering from Alzheimer's disease and Alzheimer's type dementia.].
    Myakotnykh VS; Sidenkova AP; Kravchenko ES; Borovkova TA; Khromtsova OM; Meshchaninov VN
    Adv Gerontol; 2023; 36(2):256-264. PubMed ID: 37356104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brain.
    Amano A; Sanjo N; Araki W; Anraku Y; Nakakido M; Matsubara E; Tomiyama T; Nagata T; Tsumoto K; Kataoka K; Yokota T
    J Nanobiotechnology; 2023 Jan; 21(1):36. PubMed ID: 36721182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey.
    Eliasson B; Ekelund J; Amberntsson R; Miftaraj M; Svensson AM
    Diabetes Ther; 2019 Aug; 10(4):1523-1530. PubMed ID: 31089969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.
    Patel AG; Nehete PN; Krivoshik SR; Pei X; Cho EL; Nehete BP; Ramani MD; Shao Y; Williams LE; Wisniewski T; Scholtzova H
    Brain; 2021 Aug; 144(7):2146-2165. PubMed ID: 34128045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
    Steven S; Oelze M; Hanf A; Kröller-Schön S; Kashani F; Roohani S; Welschof P; Kopp M; Gödtel-Armbrust U; Xia N; Li H; Schulz E; Lackner KJ; Wojnowski L; Bottari SP; Wenzel P; Mayoux E; Münzel T; Daiber A
    Redox Biol; 2017 Oct; 13():370-385. PubMed ID: 28667906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.